TMZ and all other reagents were provided by Sigma-Aldrich (St. Louis, MO, USA). TMZ was diluted in dimethyl sulfoxide (DMSO; Beijing Solarbio Science and Technology, Co., Ltd., Beijing, China) to a stock solution of 200 mM TMZ. Immediately before use in cell culture, the stock was diluted in media. Antibodies used for western blot analyses were obtained from Cell Signaling Technology (Danvers, MA, USA).

Human glioma cell lines U87-MG and U251-MG were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). TMZ-resistant cell lines U87-TMZ and U251-TMZ were obtained by culturing U87-MG or U251-MG cells with gradually increased doses (2–20 µM) of TMZ for 4 months. All the cells were cultured in Dulbeccos modified Eagles medium (DMEM) medium with 10% fetal bovine serum (FBS; Gibco, Vienna, Austria), 100 units/ml penicillin and 100 µg/ml streptomycin. All the cells were cultured at 37°C in an atmosphere comprising 95% air and 5% CO₂.

Cellular RNA was isolated by TRIzol reagent according to the manufacturers instructions. Briefly, the DNA was removed from the samples using DNase treatment (DNA-free kit; Ambion-Applied Biosystems, Carlsbad, CA, USA) and cDNA was synthesized from the purified RNA using Moloney murine leukemia virus reverse transcription kit (Promega, Madison, WI, USA). Primers for human PomGnT1 were: F, 5-GCCAAGTTTGCTGTGGTT CTGG-3 and R, 5-CTGGTCATTCCAGGCAGAGATG-3. Actin primer sets were used to produce a normalization control. Real-time PCR was carried out in triplicate with the SYBR-Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and a 7900HT Fast Real-Time PCR machine (Applied Biosystems).

RIPA buffer in the presence of protease inhibitor cocktail and phosphorylation inhibitor cocktail were used to extract total protein. Appropriate mount protein was loaded into 8–10% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane (Millipore, Billerica, MA, USA). Primary antibodies were incubated overnight and secondary antibodies were incubated for 1 h at the appropriate dilutions. The signal was observed and developed with Kodak film by exposure to enhanced chemiluminescence (ECL) plus western blotting detection reagents (Amersham Biosciences, Piscataway, NJ, USA). Western blot analysis was performed with antibodies against PomGnT1, TCF8, vimentin, β-catenin, Slug and actin was used as control.

The stable knockdown PomGnT1 cell lines were generated by transduction a lentiviral-mediated expression siRNA specific target of PomGnT1. Lentivirus containing the PomGnT1-specific shRNAs (shRNA sequences targeting PomGnT1 was: SH1: 5-GCCATTGAGCTCAGCAGAAGA-3; SH2: 5-GCA TCCAGCATACTCCCATCA-3; SH3: 5-AGGAGGAGCTTG AGCCCAA-3; SH4: 5-GGAGAAAGATGATGACTTC-3) were purchased from Shanghai Hanyu Biotechnology Co., Ltd. (Shanghai, China). The PomGnT1-specific shRNA lentiviral particles infected U87-TR and U251-TR cells with 10 µg/ml polybrene for 12 h. Afterwards, the medium containing viral particles was removed and replaced with fresh medium. One ‘non-target’ construct containing an shRNA sequence that did not target any known human gene was transduced separately into U87-TMZ or U251-TMZ cells to serve as a scrambled negative control. After 72 h, the cells were harvested, and the knockdown efficiency was tested by real-time PCR and western blot analysis. Transduced cell lines were named U87-TMZ PomGnT1-KD and U87-TMZ NC, and U251-TMZ PomGnT1-KD and U251-TMZ NC.

The stable overexpression of PomGnT1 cell lines were generated by transduction a lentiviral-mediated overexpression PomGnT1. An oligonucleotide coding for PomGnT1 (NM_017739) was cloned into the plasmid murine stem cell virus (pMSCV)-puro retroviral vector (Clontech Laboratories, Inc., Mountain View, CA, USA) with which 293T cells were transfected along with packaging plasmids pMD.env and pMD.gag.-pol by Shanghai Hanyu Biotechnology. The produced retroviruses were used to infect U87-MG and U251-MG cells, which were further selected in the presence of 1.0 mg/ml puromycin to establish a cell line with stable PomGnT1 overexpression (U87-PomGnT1-OE or U251-PomGnT1-OE). Cells infected with empty vector (EV) pMSCV-puro derived retroviruses were used as control (U87-NC or U251-NC). After 72 h, the cells were harvested and the overexpression efficiency was tested by real-time PCR and western blot analysis.

TMZ-sensitive and -resistant glioma cells were plated in 96-well white plates at 5×10³ cells/well, and TMZ (ranging from 200 to 1012.5 µM) was added and incubated for 48 h. A Cell Counting kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan) was used to assess cell viability. Briefly, CCK-8 reagent was added (10 µl/well), cells were maintained for 2 h, and the absorbance was read under a microplate reader (SpectraMax M5; Molecular Devices, Sunnyvale, CA, USA) at 450 nm. All half-maximal inhibitory concentration (IC₅₀) values were determined using GraphPad Prism 5 software.

Apoptosis was determined by translocation of phosphatidylserine to the cell surface using an Annexin V-FITC and PI apoptosis detection kit (BD Biosciences, San Diego, CA, USA). TMZ-sensitive and -resistant cells were plated in 6-well plates at a density of 5×10⁵ cells/well and treated with TMZ for 48 h. The cells were then harvested and washed twice in cold phosphate-buffered saline (PBS) and resuspended in Annexin V-FITC and PI for 30 min in the dark. Cell apoptosis was analyzed by using the CellQuest software on a FACSAria flow cytometer (BD Biosciences). Fluorescence was detected with an excitation wavelength of 480 nm.

For quantitative data, all results are expressed as the mean ± SD. Statistical significance between the groups was determined using the Students t-test using the SPSS 18.0 (SPSS, Inc., Chicago, IL, USA). Each experiment was repeated at least three times. P<0.01 was considered statistically significant.

TMZ is the primary and most promising therapeutic drug for GBM. In order to establish TMZ-resistant GBM cell lines, we cultured U87-MG and U251-MG cells with gradually increased doses (2–20 µM) of TMZ for 4 months. The IC₅₀ analysis results of U87-TMZ, U251-TMZ resistant cells and parental cells showed that the IC₅₀ value of both TMZ-resistant cells was increased almost 5-fold (Fig. 1A and B). We further examined the expression of PomGnT1 in parental TMZ-sensitive (U87-MG and U251-MG) and TMZ-resistant (U87-TMZ and U251-TMZ) cells. As shown in Fig. 1C and D, PomGnT1 expression was significantly elevated in TMZ-resistant cells compared with matched parental sensitive cells. These data suggest that PomGnT1 expression might be associated with TMZ-resistance in GBM cells.

Using lentivirus mediated shRNA gene knockdown system, we knocked down PomGnT1 expression in U87-TMZ and U251-TMZ cells. From the mRNA level, >90% of PomGnT1 expression was decreased. The protein level of PomGnT1 was also decreased suggesting the high efficiency of shRNA knockdown system (Fig. 2). Cells were passaged upon reaching 80% confluence. Then, we treated PomGnT1 knocked-down U87-TMZ and U251-TMZ cells with TMZ (200–1350 µM) for 48 h and detected the change of cell viability. As shown in Fig. 3, knockdown of PomGnT1 significantly reduced the viability of TMZ-resistant glioma cell lines, in a dose-dependent manner. The IC₅₀ value of TMZ for U87-resistant cells was 1033 µM and for U251-resistant cells was 1308 µM. However, the IC₅₀ value of TMZ for U87-TMZ and U251-TMZ was decreased significantly after knockdown of PomGnT1 (Table I). Hence, there was a significant decrease in IC₅₀ value for TMZ-resistant GBM cells with knockdown of PomGnT1 compared with matched parental negative cells. Through the flow cytometric analysis, we found that knockdown of PomGnT1 significantly induced apoptosis in TMZ-resistant GBM cells after treated with TMZ compared with matched parental negative cells (Fig. 4). These results indicated that loss of PomGnT1 suppressed TMZ-resistant GBM cell survival mainly by induction of apoptosis after treated with TMZ.

Using lentivirus mediated gene overexpression system, we overexpressed PomGnT1 in U87 and U251 cells. From the mRNA level, PomGnT1 expression was increased >10-fold (Fig. 5A). The protein level of PomGnT1 was also increased suggesting the high efficiency of gene overexpression system (Fig. 5B). Then, we treated PomGnT1 overexpressed U87-MG and U251-MG cells with TMZ (100–1350 µM) for 48 h and detected the change of cell viability. As shown in Fig. 6, overexpression of PomGnT1 increased the viability of TMZ-sensitive lines, in a dose-dependent manner. The IC₅₀ value of TMZ for U87-MG was 227.4 µM and for U251-MG was 364.1 µM. However, the IC₅₀ value of TMZ for U87-MG and U251-MG was increased significantly after overexpression of PomGnT1 (Table II). Hence, there was a significant increase in IC₅₀ value for TMZ-sensitive GBM cells with overexpression of PomGnT1 compared with matched parental negative cells. Through the flow cytometric analysis, we found that the percentage of apoptotic cells were decreased in TMZ-sensitive PomGnT1 overexpressed glioma cells after treated with TMZ compared with matched parental negative cells (Fig. 7). These results highlighted the importance of PomGnT1 in the progression of TMZ in treatment of TMZ-sensitive glioma cells.

To find the underlying molecular changes regulated by PomGnT1 in TMZ-resistant GBM cells, we observed the effect of PomGnT1 on TCF8, vimentin, β-catenin, Slug expression in TMZ-resistant and TMZ-sensitive GBM cells after treated with TMZ. As shown in Fig. 8, knockdown of PomGnT1 significantly inhibited expression of TCF8, vimentin, β-catenin and Slug in protein level in TMZ-resistant cells compared with matched negative control cells. Whereas, overexpression of PomGnT1 significantly elevated expression of TCF8, vimentin, β-catenin and Slug in protein level in TMZ-sensitive cells compared with matched negative control cells. These results indicate that PomGnT1-enhanced temozolomide resistance might partially be through activating epithelial-mesenchymal transition signaling in glioblastoma.